178 related articles for article (PubMed ID: 25593198)
1. The TLR7 agonist induces tumor regression both by promoting CD4⁺T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells.
Wang C; Zhou Q; Wang X; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
Oncotarget; 2015 Jan; 6(3):1779-89. PubMed ID: 25593198
[TBL] [Abstract][Full Text] [Related]
2. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
[TBL] [Abstract][Full Text] [Related]
3. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
[TBL] [Abstract][Full Text] [Related]
4. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
Kurooka M; Kaneda Y
Cancer Res; 2007 Jan; 67(1):227-36. PubMed ID: 17210703
[TBL] [Abstract][Full Text] [Related]
5. Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs.
Hackl D; Loschko J; Sparwasser T; Reindl W; Krug AB
Eur J Immunol; 2011 May; 41(5):1334-43. PubMed ID: 21469103
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells engineered to express GITRL enhance therapeutic immunity in murine Lewis lung carcinoma.
Ma J; Wang S; Ma B; Mao C; Tong J; Yang M; Wu C; Jiao Z; Lu L; Xu H
Cancer Lett; 2011 Feb; 301(2):142-50. PubMed ID: 21186078
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
8. [Anticancer immunotherapy using inactivated Sendai virus particles].
Kurooka M; Kaneda Y
Uirusu; 2007 Jun; 57(1):19-27. PubMed ID: 18040151
[TBL] [Abstract][Full Text] [Related]
9. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
[TBL] [Abstract][Full Text] [Related]
10. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
11. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
Bourquin C; Hotz C; Noerenberg D; Voelkl A; Heidegger S; Roetzer LC; Storch B; Sandholzer N; Wurzenberger C; Anz D; Endres S
Cancer Res; 2011 Aug; 71(15):5123-33. PubMed ID: 21697281
[TBL] [Abstract][Full Text] [Related]
12. Activation of toll-like receptor-7 exacerbates lupus nephritis by modulating regulatory T cells.
Gong L; Wang Y; Zhou L; Bai X; Wu S; Zhu F; Zhu YF
Am J Nephrol; 2014; 40(4):325-44. PubMed ID: 25341693
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of GITRL on dendritic cells by WGP improves anti-tumor immunity in murine Lewis lung carcinoma.
Tian J; Ma J; Ma K; Ma B; Tang X; Baidoo SE; Tong J; Yan J; Lu L; Xu H; Wang S
PLoS One; 2012; 7(10):e46936. PubMed ID: 23077535
[TBL] [Abstract][Full Text] [Related]
14. Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo.
Wurzenberger C; Koelzer VH; Schreiber S; Anz D; Vollmar AM; Schnurr M; Endres S; Bourquin C
Cancer Immunol Immunother; 2009 Jun; 58(6):901-13. PubMed ID: 18953536
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells induce regulatory T cell proliferation through antigen-dependent and -independent interactions.
Zou T; Caton AJ; Koretzky GA; Kambayashi T
J Immunol; 2010 Sep; 185(5):2790-9. PubMed ID: 20686126
[TBL] [Abstract][Full Text] [Related]
16. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.
Ozao-Choy J; Ma G; Kao J; Wang GX; Meseck M; Sung M; Schwartz M; Divino CM; Pan PY; Chen SH
Cancer Res; 2009 Mar; 69(6):2514-22. PubMed ID: 19276342
[TBL] [Abstract][Full Text] [Related]
17. Toll-Like Receptor-7 Signaling Promotes Nonalcoholic Steatohepatitis by Inhibiting Regulatory T Cells in Mice.
Roh YS; Kim JW; Park S; Shon C; Kim S; Eo SK; Kwon JK; Lim CW; Kim B
Am J Pathol; 2018 Nov; 188(11):2574-2588. PubMed ID: 30125542
[TBL] [Abstract][Full Text] [Related]
18. Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1- and Th-17-polarizing capability.
Dzopalic T; Dragicevic A; Vasilijic S; Vucevic D; Majstorovic I; Bozic B; Balint B; Colic M
Int Immunopharmacol; 2010 Nov; 10(11):1428-33. PubMed ID: 20817120
[TBL] [Abstract][Full Text] [Related]
19. Multifaceted effects of synthetic TLR2 ligand and Legionella pneumophilia on Treg-mediated suppression of T cell activation.
van Maren WW; Nierkens S; Toonen LW; Bolscher JM; Sutmuller RP; Adema GJ
BMC Immunol; 2011 Mar; 12():23. PubMed ID: 21435210
[TBL] [Abstract][Full Text] [Related]
20. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
Liu Q; Zhang C; Sun A; Zheng Y; Wang L; Cao X
J Immunol; 2009 May; 182(10):6207-16. PubMed ID: 19414774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
